REPL vs. ITOS, LXEO, TRML, ADPT, VYGR, ALVO, CRBU, AURA, TNYA, and TCRX
Should you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include iTeos Therapeutics (ITOS), Lexeo Therapeutics (LXEO), Tourmaline Bio (TRML), Adaptive Biotechnologies (ADPT), Voyager Therapeutics (VYGR), Alvotech (ALVO), Caribou Biosciences (CRBU), Aura Biosciences (AURA), Tenaya Therapeutics (TNYA), and TScan Therapeutics (TCRX). These companies are all part of the "biological products, except diagnostic" industry.
Replimune Group (NASDAQ:REPL) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.
In the previous week, Replimune Group's average media sentiment score of 1.63 beat iTeos Therapeutics' score of 0.00 indicating that Replimune Group is being referred to more favorably in the media.
iTeos Therapeutics' return on equity of -18.40% beat Replimune Group's return on equity.
Replimune Group received 123 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 72.50% of users gave iTeos Therapeutics an outperform vote while only 61.54% of users gave Replimune Group an outperform vote.
iTeos Therapeutics has higher revenue and earnings than Replimune Group. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.
Replimune Group presently has a consensus price target of $37.67, suggesting a potential upside of 486.71%. iTeos Therapeutics has a consensus price target of $30.33, suggesting a potential upside of 180.86%. Given Replimune Group's higher possible upside, analysts clearly believe Replimune Group is more favorable than iTeos Therapeutics.
92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are owned by institutional investors. 20.6% of Replimune Group shares are owned by insiders. Comparatively, 10.2% of iTeos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Replimune Group has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
Summary
iTeos Therapeutics beats Replimune Group on 7 of the 13 factors compared between the two stocks.
Get Replimune Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Replimune Group Competitors List
Related Companies and Tools
